beeldscherm schreef op 16 november 2018 16:07:
sorry maar het gaat over Takazooi/Lanatroep
Last month, the ICER published an Evidence Report stating that it would have to come down in price by 33% to align costs with the benefit to patients, based on the available data.
The ICER also found that two other HAE therapies – Haegarda from CSL Behring and Cinryze, another Shire drug – did not fit into commonly-cited cost-effectiveness thresholds
2019 I wonna scream and shout and let all out ...2019 all eyes on us